Literature DB >> 35022519

LncRNA UCA1 promotes SOX12 expression in breast cancer by regulating m6A modification of miR-375 by METTL14 through DNA methylation.

Chengpeng Zhao1, Xiaoling Ling1, Yunxia Xia2, Bingxue Yan2, Quanlin Guan3.   

Abstract

Breast cancer, a multifactorial disease, represents one of the leading causes of cancer-related morbidity and mortality in women. This study set out to elucidate the underlying mechanism by which lncRNA UCA1 affects the m6A modification of miR-375 by mediating the DNA methylation of METTL14 and then altering SOX12 expression in breast cancer. First, the expression patterns of lncRNA UCA1, miR-375, and apoptosis-related factors were quantitated by means of RT-qPCR and western blot analysis. In addition, the proliferation, invasion, and apoptosis of cells were detected using CCK-8, Transwell, and flow cytometry, respectively. RIP was performed to further uncover the interaction of lncRNA UCA1 and DNA methyltransferases, and MSP was employed for METTL14 promoter region methylation. The DNA methyltransferase enrichment in the METTL14 promoter region was measured by ChIP. The targeting relationship between miR-375 and SOX12 was confirmed by bioinformatics analysis and dual-luciferase report assay. Lastly, the aforementioned mechanism was also verified using tumor xenograft in vivo. It was found the elevated lncRNA UCA1 expression levels serve as a risk factor of poor prognosis in breast cancer. Meanwhile, silencing lncRNA UCA1 could inhibit the proliferation and invasion, but promote apoptosis of breast cancer cells by reducing the DNA methylation of METTL14 and augmenting its expression. Furthermore, METTL14 was observed to mediate the low miR-375 expression through m6A modification, leading to increased SOX12 expression levels in breast cancer. Altogether, findings obtained in our study indicated that silencing lncRNA UCA1 curbed the progression of breast cancer through the METTL14-miR-375-SOX12 axis.
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35022519     DOI: 10.1038/s41417-021-00390-w

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.854


  4 in total

1.  Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway.

Authors:  Zhuo Li; Dehai Yu; Haijun Li; You Lv; Sijie Li
Journal:  Int J Oncol       Date:  2019-01-08       Impact factor: 5.650

2.  [Expression of transcription factor SOX12 in lung adenocarcinoma and its clinical significance].

Authors:  Li Li; Tingting Zhang; Yuhua Chen; Jia Song; Yao Meng; Shu Liu; Jianming Xie
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-02-28

3.  Augmented expression levels of lncRNAs ecCEBPA and UCA1 in gastric cancer tissues and their clinical significance.

Authors:  Mojdeh Nasrollahzadeh-Khakiani; Modjtaba Emadi-Baygi; Parvaneh Nikpour
Journal:  Iran J Basic Med Sci       Date:  2017-10       Impact factor: 2.699

4.  METTL14 promotes the migration and invasion of breast cancer cells by modulating N6‑methyladenosine and hsa‑miR‑146a‑5p expression.

Authors:  Dandan Yi; Ru Wang; Xianbiao Shi; Lei Xu; Yiminu'er Yilihamu; Jianfeng Sang
Journal:  Oncol Rep       Date:  2020-02-24       Impact factor: 3.906

  4 in total
  1 in total

Review 1.  The emerging roles and mechanism of m6a in breast cancer progression.

Authors:  Mengying Zhou; Menglu Dong; Xue Yang; Jun Gong; Xinghua Liao; Qi Zhang; Zeming Liu
Journal:  Front Genet       Date:  2022-08-10       Impact factor: 4.772

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.